Heron Therapeutics, Inc. (HRTX)
Heron Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Heron Therapeutics, Inc. (HRTX) is a Biotechnology company based in US with a market capitalization of $75.4M. Revenue grew 7.4% year-over-year and free cash flow was negative at -$27.9M. This page tracks HRTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 122 employees · IPO Aug 26, 1987
Valuation
Valuation & price
$0.85as of May 17, 2026· -54.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
5.26
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$75.4M
Market cap
7.4%
Revenue growth (YoY)
73.3%
Gross margin
-$27.9M
Free cash flow (USD)
$94M
Net debt
9.3%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 11, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Heron Therapeutics, Inc.'s market cap?
Heron Therapeutics, Inc. (HRTX) has a market capitalization of $75.4M.
What is HRTX's P/E ratio?
A meaningful P/E ratio is not available for HRTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is HRTX's price-to-book (P/B) ratio?
HRTX trades at 5.26 times book value per share.
Are insiders buying HRTX stock?
SEC Form 4 filings show no open-market insider buys at Heron Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.